GPD1
Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic
Also known as: GPDA_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P21695
- Gene
- GPD1
- Ensembl
- ENSG00000167588
- Chromosome
- 12
- Canonical length
- 349 aa
- Protein class
- Disease related genes, Enzymes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes a member of the NAD-dependent glycerol-3-phosphate dehydrogenase family. The encoded protein plays a critical role in carbohydrate and lipid metabolism by catalyzing the reversible conversion of dihydroxyacetone phosphate (DHAP) and reduced nicotine adenine dinucleotide (NADH) to glycerol-3-phosphate (G3P) and NAD+. The encoded cytosolic protein and mitochondrial glycerol-3-phosphate dehydrogenase also form a glycerol phosphate shuttle that facilitates the transfer of reducing equivalents from the cytosol to mitochondria. Mutations in this gene are a cause of transient infantile hypertriglyceridemia. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Mar 2012]
Canonical amino-acid sequenceUniProt
349 residues, UniProt reviewed canonical sequence.
>P21695|GPD1
1 MASKKVCIVG SGNWGSAIAK IVGGNAAQLA QFDPRVTMWV FEEDIGGKKL TEIINTQHEN
61 VKYLPGHKLP PNVVAVPDVV QAAEDADILI FVVPHQFIGK ICDQLKGHLK ANATGISLIK
121 GVDEGPNGLK LISEVIGERL GIPMSVLMGA NIASEVADEK FCETTIGCKD PAQGQLLKEL
181 MQTPNFRITV VQEVDTVEIC GALKNVVAVG AGFCDGLGFG DNTKAAVIRL GLMEMIAFAK
241 LFCSGPVSSA TFLESCGVAD LITTCYGGRN RKVAEAFART GKSIEQLEKE LLNGQKLQGP
301 ETARELYSIL QHKGLVDKFP LFMAVYKVCY EGQPVGEFIH CLQNHPEHMLocalizationUniProt · AlphaFold · HPA
Whether an antibody against GPD1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.22
- Highest tissue expression
- 573 nTPM
Expression across tissuesHPA
Tissue
- adipose tissue: 573 nTPM
- skeletal muscle: 541 nTPM
- breast: 248 nTPM
- tongue: 202 nTPM
- kidney: 140 nTPM
- liver: 138 nTPM
Single-cell type
- adipocytes: 318 nCPM
- enterocytes: 249 nCPM
- hepatocytes: 134 nCPM
- myonuclei: 61 nCPM
- proximal tubule cells: 36 nCPM
- oligodendrocytes: 30 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- white matter: 94 nTPM
- medulla oblongata: 63 nTPM
- spinal cord: 62 nTPM
- cerebellum: 40 nTPM
- pons: 31 nTPM
- midbrain: 31 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about GPD1.
Disease | AllUniProt
Conditions GPD1 is implicated in, by any mechanism.
- Hypertriglyceridemia, transient infantile (HTGTI) MIM:614480
Disease | GeneticClinVar
21 pathogenic / likely-pathogenic of 173 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Transient infantile hypertriglyceridemia and hepatosteatosis
- Inborn genetic diseases
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.83
- gnomAD pLI
- 0.01
- gnomAD missense Z
- 0.17
- DepMap mean gene effect
- -0.04
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cellular response to cAMP
- cellular response to tumor necrosis factor
- gluconeogenesis
- glycerol-3-phosphate catabolic process
- glycerol-3-phosphate metabolic process
- glycerol-3-phosphate shuttle
- positive regulation of glycolytic process
Molecular functions
- glycerol-3-phosphate dehydrogenase [NAD(P)+] activity
- NAD binding
- protein homodimerization activity
- glycerol-3-phosphate dehydrogenase (NAD+) activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Glycerol-3-phosphate dehydrogenase, NAD-dependent, C-terminal
- Glycerol-3-phosphate dehydrogenase, NAD-dependent
- 6-phosphogluconate dehydrogenase-like, C-terminal domain superfamily
- Glycerol-3-phosphate dehydrogenase, NAD-dependent, N-terminal
- 6-phosphogluconate dehydrogenase, domain 2
- Glycerol-3-phosphate dehydrogenase, NAD-dependent, eukaryotic
- NAD(P)-binding domain superfamily
- NAD-dependent glycerol-3-phosphate dehydrogenase N-terminus
- NAD-dependent glycerol-3-phosphate dehydrogenase C-terminus
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads GPD1 as an antibody target. Whether an autoantibody or antibody against GPD1 could matter depends on whether native GPD1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
GPD1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label GPD1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...